Current Challenges and Future Directions in Lymphedema Diagnosis and Staging

Lymphedema is a chronic, progressive disorder that leads to irreversible tissue changes, functional disability, and psychosocial distress among cancer survivors. In Korea, diagnostic criteria and stage-based management systems remain fragmented despite technological progress. Conventional volume-based approaches cannot detect early physiological changes, while newer modalities such as bioimpedance spectroscopy (BIS), ultrasound, and indocyanine green (ICG) lymphography lack standardization in interpretation and application. This review examines the current limitations in Korea’s lymphedema diagnostic and staging systems and outlines evidence-based strategies for standardization, clinical integration, and outcome-driven management. Diagnostic tools, including questionnaires (LBCQ, LLIS, LYMQOL), volume-based methods (circumference, Perometer), physiological assessments (BIS, TDC), and imaging (ultrasound, lymphoscintigraphy, ICG, MRI), are inconsistently applied without harmonized timing or sensitivity thresholds. The International Society of Lymphology (ISL) 0-3 staging is seldom used to guide treatment intensity or complex decongestive therapy (CDT) duration. Moreover, partial reimbursement for imaging contrasts with the lack of coverage for BIS or ultrasound, reinforcing care inequality. An action-linked staging model aligning CDT intensity, quantitative indicators (BIS, ultrasound, volume change), and patient-reported outcomes (PROMs) is proposed. Standardized cut-offs and PROM integration can establish feedback loops between patient monitoring, clinical intervention, and policy evaluation. Unified national guidelines that integrate multimodal diagnostic standards, stage-based therapeutic linkage, and PROM-based quality assessment are essential to prevent chronic progression and ensure equitable, value-based lymphedema care.